An Act establishing a prescription drug rebate program for seniors
Take action
Record your position on this measure.
Create an account to record your position, submit testimony, or contact your legislator.
Progress
Where this bill stands in the legislative process.
- Introduced
- Passed House
- Passed Senate
- To Governor
- Became Law
Overview
This bill aims to establish a prescription drug rebate program specifically for seniors in Massachusetts. The program would likely require pharmaceutical companies to provide rebates on prescription drug costs for eligible seniors, potentially lowering their out-of-pocket expenses. It’s intended to address the rising cost of medications and improve access to affordable prescriptions for older adults. The bill has undergone several revisions and committee reviews during its legislative journey.
Key provisions
- Requires pharmaceutical companies to offer rebates on prescription drugs.
- The rebates would be directed towards seniors.
- The program’s details, such as eligibility criteria and rebate percentages, would need to be determined.
- The bill was referred to multiple committees for review and study.
- It was accompanied by a study order (H5310) to examine related issues.
- The bill was discharged to the committee on Elder Affairs and then Senate concurred.
- It was referred to the committee on Aging and Independence.
- A hearing was scheduled for June 24, 2025.
Who is affected
- Seniors in Massachusetts
- Pharmaceutical companies
- Healthcare providers
- The state’s healthcare system
Notable changes
- The bill has been modified through multiple committee reviews and legislative actions.
Bill text
Read the latest version inline or switch to a previous version.
Text extraction is in progress. View the official source.
Sponsors
Official sponsors from legislative records.
2 on record
Primary sponsor
Nicholas A. Boldyga
Cosponsor
Nicholas A. Boldyga
Arguments
Reasons offered for and against this legislation.
Arguments in favor
No arguments in favor have been submitted.
Submit yoursArguments opposed
No arguments opposed have been submitted.
Submit yours